IMMUTOL (Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases)
Investigador principal
Grup d'investigació
Font de finançament:
Unió Europea
Període:
01/05/2023 a 30/04/2027
Estat del projecte:
ACTIU
Financiació:
273,779 €
IMMUTOL is the Accelerated development and validation of an advanced therapeutic drug (ATMP) based on modified VitD3
The aim of IMMUTOL isthe fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches.
Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need. In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products.https://immutol-horizon.eu
Col·laboradors / Entitat finançadora
Fondazione Telethon ETS
Ospedale San Raffaele SRL
Institut de Investigació en Ciències de la Salut Germans Trias i Pujol
Stichting Sanquin Bloedvoorziening
Universidad de Navarra
Asphalion SL
Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag
Innovation Acta SRL
Asociación de Esclerosis Múltiple de Toledo
